Blending Treatments Worldwide for Multiple MyelomaVideo Categories: Hematological Malignancies
PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.
Dr Agarwala provides his perspective on the importance of the Global Biomarkers Consortium, World Cutaneous Malignancies Congress and the journal Personalized Medicine in Oncology.